Clinical Research Directory

Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia

The goal of this prospective cohort clinical trial is to compare the effects of roxadustat and darbepoetin alfa on hematological and iron-related parameters in adults with end-stage kidney disease (ESKD) receiving maintenance hemodialysis who have erythropoietin-resistant anemia. The main questions it aims to answer are: * Do hematological and iron-related parameters change following treatment with roxadustat or darbepoetin alfa? * Are there differences in treatment response between roxadustat and darbepoetin alfa? Researchers will compare oral roxadustat with subcutaneous darbepoetin alfa to evaluate changes in hematological and iron-related parameters over 12 weeks. Researchers investigate patients who: * Receive either roxadustat 70 mg orally three times weekly or darbepoetin alfa subcutaneously according to one of two permitted weight-based dosing regimens. * Undergo laboratory assessments at baseline and after 12 weeks of treatment, including hemoglobin, red blood cell indices, and iron-related parameters.

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat